Skip to contentA
Abbott Laboratories
A
ABTAbbott Laboratories Q3 2025 · 10-Q
Revenue$11.37B$11.37B+6.9% vs Q3 2024 Net Income$1.64B$1.64B−0.1% vs Q3 2024 EPS Diluted$0.94$0.94±0.0% vs Q3 2024 Operating Income$2,057,000,000+10.7% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Abbott Laboratories · CIK 1800 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$2,291,000,000+6.6% Margins · derivedOperating margin18.1%+0.6 pt vs Q3 2024
Net margin14.5%−1.0 pt vs Q3 2024
ended Sep 30, 2025 · filed Oct 29, 2025 · 29 d after period end